Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A promising combo for a tough-to-treat cancer: Updated data from the phase 1/2 GOBLET trial show that pelareorep plus atezolizumab produced a median duration of response of ~15 months in patients with second-line or later squamous cell anal cancer (SCAC). All responders survived beyond 12 months, with several crossing the 24-month mark. The results are fueling plans for a potential accelerated FDA approval pathway.
A promising combo for a tough-to-treat cancer
Updated data from cohort 4 of the phase 1/2 GOBLET trial reveal that pelareorep combined with atezolizumab (Tecentriq) is generating durable responses in patients with previously treated squamous cell anal cancer (SCAC). The median duration of response (DOR) clocked in at approximately 15 months, and median overall survival (OS) has not yet been reached — a notable milestone in a disease with limited second-line options.
Every patient who responded to the combination survived beyond 12 months, with multiple patients surpassing the 24-month mark. These results compare favorably to the 9.5-month median DOR seen with retifanlimab monotherapy in a similar population, though no head-to-head comparison has been conducted.
By the Numbers
Why it matters: Pelareorep already holds FDA fast track designation in SCAC, and Oncolytics Biotech is now eyeing an accelerated approval pathway. The company also plans to explore expanding the pelareorep + checkpoint inhibitor platform into other HPV-driven cancers, including head and neck cancer.
